



Department of Health and Human Services  
11 State House Station  
Augusta, Maine 04333-0011  
TTY Users: Dial 711 (Maine Relay)

**To:** MaineCare Providers  
**From:** Jill Kingsbury – MaineCare Pharmacy Director  
**Date:** June 12, 2017  
**Re:** Adderall XR update for 2017

MaineCare would like to inform all prescribers and pharmacy providers that, effective July 1, 2017, members 21 years of age or younger who were previously grandfathered on Adderall XR for the treatment of ADHD will be required to transition to the currently preferred Vyvanse. The initial notice was sent 11-14-2016.

With the introduction of Vyvanse as the preferred long-acting amphetamine, members were originally allowed (“grandfathered”) to remain on Adderall XR without a prior trial of Vyvanse. Note, beginning Feb 1<sup>st</sup>, 2017, those members 22 years of age or older without a prior trial of the preferred product Vyvanse were required to transition to that medication.

MaineCare understands that the transition to Vyvanse may take several months, so an extended notice was sent to allow prescribers the time needed to convert patients. Approximately 40% of MaineCare members on Adderall XR have previously tried Vyvanse and the remaining percentage would require a new trial.

If you have any questions, please contact the Change Healthcare Provider Services Help Desk at 1-888-445-0497 or Pharmacy Help Desk at 1-888-420-9711.

---